Effect of Lignosilicon on the Content and Antioxidant Activity of the Polyphenols of Buckwheat Fagopyrum esculentum Moench

Lignin preparations, introduced into soil jointly with buckwheat Fagopyrum esculentum Moench, variety 'Aiva' (cultivated throughout Latvia) seeds during the sowing in quantities of 20 kg ha-1 and 40 kg ha-1, exerted a favourable effect on the ned in alcohol extracts from the biomass of different morphological parts of buckwheat, were represented mainly by rutin. The content of rutin in the ethanol extracts from the biomass of flowers with bract reached the maximum values in the phase of accomplishing blooming - beginning of fruit formation to be 2.74% in terms of dry mass (exceeding the rutin content development of plants and the synthesis of flavonoids in flowers with bract. Flavonoids, determin the control by 65%) in the variant with 40 kg ha-1 of Lignosilicon. Lignin preparations favoured the increase in the radical scavenging capacity of the alcohol extracts of the biomass of flowers with bract of buckwheat, as well as grain and hulls. The increment of the buckwheat grain crop, in comparison with the control on the background of 40 kg ha-1 of lignin, was 12%, and that on the background of 20 kg ha-1 and 40 kg/ha of Lignosilicon 10% and 15%, respectively

Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.

AIMS Atherosclerotic cardiovascular disease (ACVD) is a major cause of mortality and morbidity worldwide, and increased low-density lipoproteins (LDLs) play a critical role in development and progression of atherosclerosis. Here, we examined for the first time gut immunomodulatory effects of the microbiota-derived metabolite propionic acid (PA) on intestinal cholesterol metabolism. METHODS AND RESULTS Using both human and animal model studies, we demonstrate that treatment with PA reduces blood total and LDL cholesterol levels. In apolipoprotein E-/- (Apoe-/-) mice fed a high-fat diet (HFD), PA reduced intestinal cholesterol absorption and aortic atherosclerotic lesion area. Further, PA increased regulatory T-cell numbers and interleukin (IL)-10 levels in the intestinal microenvironment, which in turn suppressed the expression of Niemann-Pick C1-like 1 (Npc1l1), a major intestinal cholesterol transporter. Blockade of IL-10 receptor signalling attenuated the PA-related reduction in total and LDL cholesterol and augmented atherosclerotic lesion severity in the HFD-fed Apoe-/- mice. To translate these preclinical findings to humans, we conducted a randomized, double-blinded, placebo-controlled human study (clinical trial no. NCT03590496). Oral supplementation with 500 mg of PA twice daily over the course of 8 weeks significantly reduced LDL [-15.9 mg/dL (-8.1%) vs. -1.6 mg/dL (-0.5%), P = 0.016], total [-19.6 mg/dL (-7.3%) vs. -5.3 mg/dL (-1.7%), P = 0.014] and non-high-density lipoprotein cholesterol levels [PA vs. placebo: -18.9 mg/dL (-9.1%) vs. -0.6 mg/dL (-0.5%), P = 0.002] in subjects with elevated baseline LDL cholesterol levels. CONCLUSION Our findings reveal a novel immune-mediated pathway linking the gut microbiota-derived metabolite PA with intestinal Npc1l1 expression and cholesterol homeostasis. The results highlight the gut immune system as a potential therapeutic target to control dyslipidaemia that may introduce a new avenue for prevention of ACVDs